|
MiCardia Corporation is an early
stage venture dedicated to designing,
developing and commercializing minimally invasive methods to treat
heart valve disease – Mitral Valve Regurgitation (MR), Tricuspid
Valve Regurgitation and Congestive Heart Failure (CHF). The
Company was formed in November 2004.
Since its inception, the company has built an experienced technical
and clinical team, while creating a comprehensive intellectual
property portfolio. Proof of concept has been completed for
a Dynamically Activated Annuloplasty Ring with novel methods for
off-pump intra-operative and chronic percutaneous activation
methods. |
